Research Paper Volume 12, Issue 22 pp 22975—23003

Figure 7. KIF14 silencing synergizes with sorafenib to suppress subcutaneous tumors formed from sorafenib-resistant cells in vivo. (A) Subcutaneous tumors were established in mice that received different treatments for 15 days as described in the Materials and Methods section. The volume (mm³) of tumors was recorded. (B and C) Tumors harvested at the end of experiments were weighed (B) and photographed (C). (D) Representative images of tumor sections stained with anti-Ki-67 Ab (top) and subjected to TUNEL assay (bottom; magnification, ×200). (E) The proliferation index (%) and (F) apoptosis index (%) were quantified. (G and H) Western blotting of lysates of tumors harvested from (A) at the end of experiments (G). The density of each band was normalized to that of β-actin (H). Scale bar = 500 μm. “*” Indicates P<0.05 and “**” indicates P<0.001.